Literature DB >> 31529195

The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.

Kirsten E L Garner1,2, Nathan J Hull3, Andrew H Sims4, Rebecca Lamb5, Robert B Clarke3.   

Abstract

Triple negative breast cancer (TNBC) is the most lethal breast cancer subtype. Extended periods of lactation protect against breast cancer development, but the mechanisms underlying this protection are unknown. We examined the effects of the milk protein alpha-casein over expression in the triple negative MDA-MB-231 breast cancer cell line. The effects of recombinant alpha-casein added exogenously to MDA-MB-231 breast cancer cells, and immortalised human fibroblasts were also investigated. We used transcriptional reporters to understand the signalling pathways downstream of alpha-casein in breast cancer cells and these fibroblasts that were activated by breast cancer cells. To extend our findings to the clinical setting, we analysed public gene expression datasets to further understand the relevance of these signalling pathways in triple negative breast cancer cells and patient samples. Finally, we used small molecular inhibitors to target relevant pathways and highlight these as potential candidates for the treatment of TN breast cancer. High levels of alpha-casein gene expression were predictive of good prognosis across 263 TNBC patient tumour samples. Alpha-casein over expression or exogenous addition reduces cancer stem cell (CSC) activity. HIF-1alpha was identified to be a key downstream target of alpha-casein, in both breast cancer cells and activated fibroblasts, and STAT transcription factors to be upstream of HIF-1alpha. Interestingly, HIF-1alpha is regulated by STAT3 in breast cancer cells, but STAT1 is the regulator of HIF-1alpha in activated fibroblasts. In analysis of 573 TNBC patient samples, alpha-casein expression, inversely correlated to HIF-1alpha, STAT3 and STAT1. STAT1 and STAT3 inhibitors target HIF-1alpha signalling in activated fibroblasts and MDA-MB-231 breast cancer cells respectively, and also abrogate CSC activities. Our findings provide an explanation for the protective effects of lactation in TNBC. Clinical data correlates high alpha-casein expression with increased recurrence-free survival in TNBC patients. Mechanistically, alpha-casein reduces breast cancer stem cell activity in vitro, and STAT3 and STAT1 were identified as regulators of pro-tumorigenic HIF-1alpha signalling in breast cancer cells and fibroblasts respectively.

Entities:  

Keywords:  Breast cancer stem cells; Cancer activated fibroblasts; HIF-1alpha. STAT

Year:  2019        PMID: 31529195     DOI: 10.1007/s10911-019-09435-1

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  41 in total

1.  Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.

Authors:  Rulla M Tamimi; Graham A Colditz; Aditi Hazra; Heather J Baer; Susan E Hankinson; Bernard Rosner; Jonathan Marotti; James L Connolly; Stuart J Schnitt; Laura C Collins
Journal:  Breast Cancer Res Treat       Date:  2011-08-10       Impact factor: 4.872

2.  Identification of Cancer-Associated Fibroblasts in Circulating Blood from Patients with Metastatic Breast Cancer.

Authors:  Zheng Ao; Sanket H Shah; Leah M Machlin; Ritesh Parajuli; Philip C Miller; Siddarth Rawal; Anthony J Williams; Richard J Cote; Marc E Lippman; Ram H Datar; Dorraya El-Ashry
Journal:  Cancer Res       Date:  2015-10-15       Impact factor: 12.701

3.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

Review 4.  Fibroblasts in cancer.

Authors:  Raghu Kalluri; Michael Zeisberg
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

Review 5.  Triple-negative breast cancer: therapeutic options.

Authors:  Susan Cleator; Wolfgang Heller; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

6.  Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.

Authors:  Christopher I Li; Elisabeth F Beaber; Mei-Tzu Chen Tang; Peggy L Porter; Janet R Daling; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2012-12-09       Impact factor: 4.872

7.  STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells.

Authors:  M R Pawlus; L Wang; C-J Hu
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

8.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Authors:  Xiaoxian Li; Michael T Lewis; Jian Huang; Carolina Gutierrez; C Kent Osborne; Meng-Fen Wu; Susan G Hilsenbeck; Anne Pavlick; Xiaomei Zhang; Gary C Chamness; Helen Wong; Jeffrey Rosen; Jenny C Chang
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

9.  Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.

Authors:  Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Authors:  Gabriella Honeth; Pär-Ola Bendahl; Markus Ringnér; Lao H Saal; Sofia K Gruvberger-Saal; Kristina Lövgren; Dorthe Grabau; Mårten Fernö; Ake Borg; Cecilia Hegardt
Journal:  Breast Cancer Res       Date:  2008-06-17       Impact factor: 6.466

View more
  2 in total

1.  Identification of Prognostic Immune Genes in Bladder Urothelial Carcinoma.

Authors:  Qisheng Su; Yan Sun; Zunni Zhang; Zheng Yang; Yuling Qiu; Xiaohong Li; Wuning Mo
Journal:  Biomed Res Int       Date:  2020-01-20       Impact factor: 3.411

2.  Role of hypoxia inducible factor-1 in cancer stem cells (Review).

Authors:  Qi Zhang; Zhenzhen Han; Yanbo Zhu; Jingcheng Chen; Wei Li
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.